drugset / Trial / NCT03949101

Atropine for Children and Adolescent Myopia Progression Study

NCT03949101

RandomizedParallel-groupOpen-labelTreatment

Summary

Investigators are going to conduct a randomized controlled trial that myopic children are randomly allocated into two groups: combined use of 1% atropine and 0.01% atropine (experimental group) and 0.01% atropine (control group) in order to explore a better way to control myopia progression and eliminate adverse effects at the same time, provide reliably evidence for clinical guideline of atropine use in children, and investigate the mechanism of atropine on eyes.

Timeline

Start
2019-05-08
Primary completion
2021-05-08
Completion
2021-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atropine Other / unclassified 0.01 % Topical

Indications